APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nivolumab Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nivolumab Drugs Market Outlook and Growth Opportunities 2026

2 January 2026194 pages

Choose your research edition.

Industry ResearchNivolumab Drugs Industry Research Report 2026109 pages · $2,950 USDIndustry Growth & TrendsGlobal Nivolumab Drugs Industry Growth and Trends Forecast to 203270 pages · $3,450 USDMarket StructureGlobal Nivolumab Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nivolumab Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Nivolumab Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Nivolumab Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nivolumab Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nivolumab Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nivolumab Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nivolumab Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nivolumab Drugs market include Bristol-Myers Squibb and Ono Pharmaceutical among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nivolumab Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nivolumab Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nivolumab Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nivolumab Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Nivolumab Drugs Segment by Company

Bristol-Myers Squibb

Ono Pharmaceutical

Nivolumab Drugs Segment by Type

10ml

24ml

4ml

Nivolumab Drugs Segment by Application

Retail Pharmacy

Hospital Pharmacy

Other

Nivolumab Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Nivolumab Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Nivolumab Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nivolumab Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Nivolumab Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nivolumab Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nivolumab Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nivolumab Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nivolumab Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nivolumab Drugs industry.

Chapter 3: Detailed analysis of Nivolumab Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Nivolumab Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Nivolumab Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nivolumab Drugs Industry Trends Table 2. Nivolumab Drugs Industry Drivers Table 3. Nivolumab Drugs Industry Opportunities and Challenges Table 4. Nivolumab Drugs Industry Restraints Table 5. Global Nivolumab Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nivolumab Drugs Revenue Share by Company (2021-2026) Table 7. Global Nivolumab Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Nivolumab Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Nivolumab Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Nivolumab Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Nivolumab Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Nivolumab Drugs Company, Product Type & Application Table 13. Global Nivolumab Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Nivolumab Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 10ml Table 18. Significant Companies of 24ml Table 19. Significant Companies of 4ml Table 20. Global Nivolumab Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Nivolumab Drugs Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Nivolumab Drugs Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Nivolumab Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Nivolumab Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Nivolumab Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Nivolumab Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Nivolumab Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Nivolumab Drugs Sales Value Share by Type (2021-2026) Table 29. Global Nivolumab Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Retail Pharmacy Table 31. Significant Companies of Hospital Pharmacy Table 32. Significant Companies of Other Table 33. Global Nivolumab Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Nivolumab Drugs Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Nivolumab Drugs Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Nivolumab Drugs Sales Volume Share by Application (2021-2026) Table 37. Global Nivolumab Drugs Sales Volume Share by Application (2027-2032) Table 38. Global Nivolumab Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Nivolumab Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Nivolumab Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Nivolumab Drugs Sales Value Share by Application (2021-2026) Table 42. Global Nivolumab Drugs Sales Value Share by Application (2027-2032) Table 43. Global Nivolumab Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Nivolumab Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Nivolumab Drugs Sales Market Share by Region (2021-2026) Table 46. Global Nivolumab Drugs Sales by Region (2027-2032) & (K Units) Table 47. Global Nivolumab Drugs Sales Market Share by Region (2027-2032) Table 48. Global Nivolumab Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Nivolumab Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Nivolumab Drugs Sales Value Share by Region (2021-2026) Table 51. Global Nivolumab Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Nivolumab Drugs Sales Value Share by Region (2027-2032) Table 53. Global Nivolumab Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Nivolumab Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Nivolumab Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Nivolumab Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Nivolumab Drugs Sales by Country (2021-2026) & (K Units) Table 58. Global Nivolumab Drugs Sales Market Share by Country (2021-2026) Table 59. Global Nivolumab Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global Nivolumab Drugs Sales Market Share by Country (2027-2032) Table 61. Global Nivolumab Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Nivolumab Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global Nivolumab Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Nivolumab Drugs Sales Value Market Share by Country (2027-2032) Table 65. Bristol-Myers Squibb Company Information Table 66. Bristol-Myers Squibb Business Overview Table 67. Bristol-Myers Squibb Nivolumab Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Bristol-Myers Squibb Nivolumab Drugs Product Portfolio Table 69. Bristol-Myers Squibb Recent Development Table 70. Ono Pharmaceutical Company Information Table 71. Ono Pharmaceutical Business Overview Table 72. Ono Pharmaceutical Nivolumab Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Ono Pharmaceutical Nivolumab Drugs Product Portfolio Table 74. Ono Pharmaceutical Recent Development Table 75. Key Raw Materials Table 76. Raw Materials Key Suppliers Table 77. Nivolumab Drugs Distributors List Table 78. Nivolumab Drugs Customers List Table 79. Research Programs/Design for This Report Table 80. Authors List of This Report Table 81. Secondary Sources Table 82. Primary Sources List of Figures Figure 1. Nivolumab Drugs Product Image Figure 2. Global Nivolumab Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nivolumab Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Nivolumab Drugs Sales (2021-2032) & (K Units) Figure 5. Global Nivolumab Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Nivolumab Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 10ml Image Figure 10. 24ml Image Figure 11. 4ml Image Figure 12. Global Nivolumab Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Nivolumab Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Nivolumab Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Nivolumab Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Nivolumab Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Nivolumab Drugs Sales Value Share by Type (2021-2032) Figure 18. Retail Pharmacy Image Figure 19. Hospital Pharmacy Image Figure 20. Other Image Figure 21. Global Nivolumab Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Nivolumab Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Nivolumab Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global Nivolumab Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Nivolumab Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Nivolumab Drugs Sales Value Share by Application (2021-2032) Figure 27. Global Nivolumab Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Nivolumab Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Nivolumab Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Nivolumab Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Nivolumab Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Nivolumab Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Nivolumab Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Nivolumab Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Nivolumab Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Nivolumab Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Nivolumab Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Nivolumab Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Nivolumab Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Nivolumab Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Nivolumab Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Nivolumab Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Nivolumab Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 10ml
  • 24ml
  • 4ml
Applications
  • Retail Pharmacy
  • Hospital Pharmacy
  • Other
Companies covered
  • Bristol-Myers Squibb
  • Ono Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Nivolumab Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Nivolumab Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Nivolumab Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Nivolumab Drugs Market Dynamics
  1. 2.1 Nivolumab Drugs Industry Trends
  2. 2.2 Nivolumab Drugs Industry Drivers
  3. 2.3 Nivolumab Drugs Industry Opportunities and Challenges
  4. 2.4 Nivolumab Drugs Industry Restraints
3 Nivolumab Drugs Market by Company
  1. 3.1 Global Nivolumab Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Nivolumab Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Nivolumab Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Nivolumab Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Nivolumab Drugs Company Ranking (2024-2026)
  6. 3.6 Global Nivolumab Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Nivolumab Drugs Company Product Type and Application
  8. 3.8 Global Nivolumab Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Nivolumab Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Nivolumab Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Nivolumab Drugs Market by Type
  1. 4.1 Nivolumab Drugs Type Introduction
  2. 4.1.1 10ml
  3. 4.1.2 24ml
  4. 4.1.3 4ml
  5. 4.2 Global Nivolumab Drugs Sales Volume by Type
  6. 4.2.1 Global Nivolumab Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Nivolumab Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Nivolumab Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Nivolumab Drugs Sales Value by Type
  10. 4.3.1 Global Nivolumab Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Nivolumab Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Nivolumab Drugs Sales Value Share by Type (2021-2032)
5 Nivolumab Drugs Market by Application
  1. 5.1 Nivolumab Drugs Application Introduction
  2. 5.1.1 Retail Pharmacy
  3. 5.1.2 Hospital Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Nivolumab Drugs Sales Volume by Application
  6. 5.2.1 Global Nivolumab Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nivolumab Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Nivolumab Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Nivolumab Drugs Sales Value by Application
  10. 5.3.1 Global Nivolumab Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Nivolumab Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Nivolumab Drugs Sales Value Share by Application (2021-2032)
6 Nivolumab Drugs Regional Sales and Value Analysis
  1. 6.1 Global Nivolumab Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nivolumab Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Nivolumab Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Nivolumab Drugs Sales by Region (2027-2032)
  5. 6.3 Global Nivolumab Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Nivolumab Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Nivolumab Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Nivolumab Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Nivolumab Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Nivolumab Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Nivolumab Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Nivolumab Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Nivolumab Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Nivolumab Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Nivolumab Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Nivolumab Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Nivolumab Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Nivolumab Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Nivolumab Drugs Sales Value Share by Country, 2025 VS 2032
7 Nivolumab Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Nivolumab Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nivolumab Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Nivolumab Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Nivolumab Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Nivolumab Drugs Sales by Country (2027-2032)
  6. 7.4 Global Nivolumab Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Nivolumab Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Nivolumab Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Nivolumab Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Nivolumab Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Nivolumab Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb
  2. 8.1.1 Bristol-Myers Squibb Company Information
  3. 8.1.2 Bristol-Myers Squibb Business Overview
  4. 8.1.3 Bristol-Myers Squibb Nivolumab Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb Nivolumab Drugs Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb Recent Developments
  7. 8.2 Ono Pharmaceutical
  8. 8.2.1 Ono Pharmaceutical Company Information
  9. 8.2.2 Ono Pharmaceutical Business Overview
  10. 8.2.3 Ono Pharmaceutical Nivolumab Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Ono Pharmaceutical Nivolumab Drugs Product Portfolio
  12. 8.2.5 Ono Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nivolumab Drugs Value Chain Analysis
  2. 9.1.1 Nivolumab Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nivolumab Drugs Sales Mode & Process
  6. 9.2 Nivolumab Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nivolumab Drugs Distributors
  9. 9.2.3 Nivolumab Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst